Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Income (2021 - 2025)

Historic Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $24.0 million.

  • Kiniksa Pharmaceuticals International's Operating Income rose 34871.61% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 24542.61%. This contributed to the annual value of -$45.6 million for FY2024, which is 8104.46% down from last year.
  • Kiniksa Pharmaceuticals International's Operating Income amounted to $24.0 million in Q3 2025, which was up 34871.61% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Operating Income ranged from a high of $46.4 million in Q3 2022 and a low of -$49.3 million during Q1 2021
  • For the 5-year period, Kiniksa Pharmaceuticals International's Operating Income averaged around -$8.4 million, with its median value being -$10.9 million (2023).
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 2392592.59% in 2024, then surged by 1733076.92% in 2025.
  • Kiniksa Pharmaceuticals International's Operating Income (Quarter) stood at -$36.1 million in 2021, then skyrocketed by 116.74% to $6.0 million in 2022, then tumbled by 98.66% to $81000.0 in 2023, then crashed by 23925.93% to -$19.3 million in 2024, then skyrocketed by 224.47% to $24.0 million in 2025.
  • Its Operating Income was $24.0 million in Q3 2025, compared to $20.2 million in Q2 2025 and $13.3 million in Q1 2025.